These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31384431)

  • 41. The Prognostic Impact of Serum Uric Acid on Disease Severity and 5-Year Mortality in Patients With Idiopathic Pulmonary Artery Hypertension.
    Yan L; Huang Z; Zhao Z; Zhao Q; Tang Y; Zhang Y; Li X; Duan A; Luo Q; Liu Z
    Front Med (Lausanne); 2022; 9():805415. PubMed ID: 35155496
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Application of the DETECT algorithm for detection of risk of pulmonary arterial hypertension in systemic sclerosis: data from a Czech tertiary centre.
    Soukup T; Pudil R; Kubinova K; Hromadkova L; Dusek J; Tosovsky M; Bradna P; Hrncir Z; Bures J
    Rheumatology (Oxford); 2016 Jan; 55(1):109-14. PubMed ID: 26320140
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
    Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
    Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Pulmonary arterial hypertension associated with connective tissue diseases].
    Legendre P; Mouthon L
    Presse Med; 2014 Sep; 43(9):957-69. PubMed ID: 25129118
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 2013 ACR/EULAR systemic sclerosis classification criteria in patients with associated pulmonary arterial hypertension.
    Joven BE; Escribano P; Andreu JL; Loza E; Jimenez C; de Yebenes MJG; Ruiz-Cano MJ; Carmona L; Carreira PE
    Semin Arthritis Rheum; 2018 Jun; 47(6):870-876. PubMed ID: 29126717
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis.
    Lefèvre G; Dauchet L; Hachulla E; Montani D; Sobanski V; Lambert M; Hatron PY; Humbert M; Launay D
    Arthritis Rheum; 2013 Sep; 65(9):2412-23. PubMed ID: 23740572
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic Challenges And Advances In The Management Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension (SSc-PAH).
    Argula RG; Ward C; Feghali-Bostwick C
    Ther Clin Risk Manag; 2019; 15():1427-1442. PubMed ID: 31853179
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Uric Acid as a potential biomarker of pulmonary arterial hypertension in patients with sickle cell disease.
    Joshi K; Anjum F; Gowda S; Damania D; Graham-Hill S; Gillette P; Zein J; Jamaleddine G; Demetis S; Wadgaonkar R
    Indian J Hematol Blood Transfus; 2011 Jun; 27(2):96-100. PubMed ID: 22654300
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost savings with a new screening algorithm for pulmonary arterial hypertension in systemic sclerosis.
    Quinlivan A; Thakkar V; Stevens W; Morrisroe K; Prior D; Rabusa C; Youssef P; Gabbay E; Roddy J; Walker JG; Zochling J; Sahhar J; Nash P; Lester S; Rischmueller M; Proudman SM; Nikpour M
    Intern Med J; 2015 Nov; 45(11):1134-40. PubMed ID: 26337683
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease.
    Johnson SR; Granton JT; Tomlinson GA; Grosbein HA; Le T; Lee P; Seary ME; Hawker GA; Feldman BM
    J Rheumatol; 2012 Feb; 39(2):276-85. PubMed ID: 22247353
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension.
    Morrisroe K; Stevens W; Huq M; Prior D; Sahhar J; Ngian GS; Celermajer D; Zochling J; Proudman S; Nikpour M;
    Arthritis Res Ther; 2017 Jun; 19(1):122. PubMed ID: 28576149
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Decreased biventricular longitudinal strain in patients with systemic sclerosis is mainly caused by pulmonary hypertension and not by systemic sclerosis per se.
    Lindholm A; Hesselstrand R; Rådegran G; Arheden H; Ostenfeld E
    Clin Physiol Funct Imaging; 2019 May; 39(3):215-225. PubMed ID: 30597705
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Insulin-like growth factor binding protein-2: a new circulating indicator of pulmonary arterial hypertension severity and survival.
    Yang J; Griffiths M; Nies MK; Brandal S; Damico R; Vaidya D; Tao X; Simpson CE; Kolb TM; Mathai SC; Pauciulo MW; Nichols WC; Ivy DD; Austin ED; Hassoun PM; Everett AD
    BMC Med; 2020 Oct; 18(1):268. PubMed ID: 33019943
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension.
    Mathai SC; Bueso M; Hummers LK; Boyce D; Lechtzin N; Le Pavec J; Campo A; Champion HC; Housten T; Forfia PR; Zaiman AL; Wigley FM; Girgis RE; Hassoun PM
    Eur Respir J; 2010 Jan; 35(1):95-104. PubMed ID: 19643943
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry.
    Chung L; Fairchild RM; Furst DE; Li S; Alkassab F; Bolster MB; Csuka ME; Derk CT; Domsic RT; Fischer A; Frech TM; Gomberg-Maitland M; Gordon JK; Hinchcliff M; Hsu V; Hummers LK; Khanna D; Medsger TAJ; Molitor JA; Preston IR; Schiopu E; Shapiro L; Hant F; Silver R; Simms R; Varga J; Steen VD; Zamanian RT
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):106-113. PubMed ID: 27908301
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patients with systemic sclerosis-associated pulmonary arterial hypertension express a genomic signature distinct from patients with interstitial lung disease.
    Moll M; Christmann RB; Zhang Y; Whitfield ML; Wang YM; Rice L; Stratton E; Lafyatis R; Farber HW
    J Scleroderma Relat Disord; 2018 Oct; 3(3):242-248. PubMed ID: 30498788
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Brief Report: Association of Elevated Adipsin Levels With Pulmonary Arterial Hypertension in Systemic Sclerosis.
    Korman BD; Marangoni RG; Hinchcliff M; Shah SJ; Carns M; Hoffmann A; Ramsey-Goldman R; Varga J
    Arthritis Rheumatol; 2017 Oct; 69(10):2062-2068. PubMed ID: 28651038
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China.
    Zhao J; Wang Q; Liu Y; Tian Z; Guo X; Wang H; Lai J; Huang C; Yang X; Li M; Zeng X
    Int J Cardiol; 2017 Jun; 236():432-437. PubMed ID: 28159359
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL).
    Preston IR; Roberts KE; Miller DP; Sen GP; Selej M; Benton WW; Hill NS; Farber HW
    Circulation; 2015 Dec; 132(25):2403-11. PubMed ID: 26510696
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTAR-PAH study: Baseline characteristics and risk factors.
    Zhang N; Li M; Qian J; Wang Q; Zhao J; Yang Z; Tian Z; Zhang X; Zuo X; Zhang M; Zhu P; Ye S; Zhang W; Zheng Y; Qi W; Li Y; Zhang Z; Ding F; Gu J; Liu Y; Wei W; Zeng X
    Int J Rheum Dis; 2019 May; 22(5):921-928. PubMed ID: 30746850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.